Please login to the form below

Not currently logged in
Email:
Password:

Grünenthal buys Zomig rights as AZ slimming drive continues

Acquires global rights outside Japan to the migraine drug

AstraZeneca

Grünenthal has acquired the rights to AstraZeneca’s migraine drug Zomig for up to $302m as the UK pharma firm continues to sharpen its strategic focus.

AstraZeneca has sold a raft of older or non-core products over the past two years, including a $230m deal with Grünenthal for gout drug Zurampic.

Mark Mallon, EVP, global product and portfolio strategy at AstraZeneca, said: “Grünenthal is an established partner with expertise in the treatment of pain. It is well placed to ensure patients continue to benefit from Zomig, and to extend the commercial potential of the medicine through its dedicated salesforce.”

The companies’ latest agreement covers global rights outside Japan to Zomig (zolmitriptan), a treatment for migraines and cluster headaches for which Grünenthal will pay $200m up front and up to $102m in milestones.

Gabriel Baertschi, CEO of Grünenthal, said: “The acquisition of the well-established Zomig products complements our existing pain portfolio. Migraine has been one of the very few main pain indications we haven’t yet been able to offer a solution for.

“This is an important step to reach our ambition to become a €2bn company by 2022. It will also support our efforts to bring four to five innovative products to market in the same timeframe.”

It’s thought that more than 75 million people around the world suffering from migraine attacks, which can lead to nausea and vomiting.

AZ has been busy focusing its efforts on its core therapeutic categories - namely oncology, inflammation and autoimmunity and cardiovascular/metabolic diseases - as it tries to meet chief executive Pascal Soriot's objective of boosting sales to $45bn by 2023.

This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood pressure brands).

Article by
Dominic Tyer

7th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics